Q&A: How 3PLs are navigating the latest pharma trends
Pharmaceutical third-party logistics (3PL) providers are moving beyond traditional warehousing into more holistic and strategic commercialization support. At the same…
Pharmaceutical third-party logistics (3PL) providers are moving beyond traditional warehousing into more holistic and strategic commercialization support. At the same…
Each year in the US, more than 21,000 women will receive a new diagnosis of ovarian cancer according to the…
Nephrology has long been a difficult space for drug development: trials were slow, complex, high cost, and often unrewarding, constrained…
For years, healthcare organizations have focused on enabling clinical mobility by giving clinicians access to systems, communication tools, and patient…
From novel drug targets for chronic kidney disease (CKD)[i] to advances in multifunctional drugs promising better efficacy, recent developments in…
In the first part of our Q&A with Grace Breen, SVP, Quality, Sharp, we explored valuable insights derived from her…
CGTs offer potentially life-changing treatment for a broad spectrum of complex diseases, from genetic conditions to cancers. The pace of…
Oncology drug development has shifted decisively towards precision immunotherapies, where biomarker-defined patient populations play a pivotal role. Immuno-oncology now represents…
Enrollment challenges continue to be a defining constraint in nephrology research. In a January 2026 snapshot of GlobalData’s clinical trial…
Healthcare is entering a new era of digital transformation. In the US, competition among leading providers is driving rapid adoption…